Hospital Pharmacy - June 2018 - 147

147

Walker
Table 1. New Treatment Options.
Generic name

Sponsor

Phase III drugs
Aramchol
Galmed

Drug class

Cenicriviroc Allergan

Fatty acid /bile acid
conjugate
CCR2/CCR5 inhibitor

Elafibranor

Genfit

PPAR agonist

Selonsertib

Gilead

ASK1 Inhibitor

Novartis, Conatus

Caspase inhibitor

Phase II drugs
Emricasan
GS-0976

NGM282

Efficacy summary
In a 3-month, 60 NAFLD patient, phase II trial, aramchol reduced liver
fat compared with placebo.7
Allergan announced that in a 2-year, 289-patient trial, cenicriviroc did
not decrease inflammation or liver cell damage in NASH patients
compared with placebo.
Genfit announced that in a 52-week, 276-patient, phase II trial,
elafibranor did not resolve NASH without fibrosis worsening
compared with palcebo.
In a 24-week, 72-patient, phase II trial, selonsertib demonstrated
improvements in liver fibrosis. The addition of simtuzumab did not
improve results.8

Conatus announced that in an 86-patient, phase II trial, emricasan
decreased progression of MELD scores and improved Child-Pugh
scores in patients with NASH cirrhosis.
Gilead
Acetyl-CoA carboxylase Gilead announced that in a 126-patient, phase II trial, 48% of NASH
inhibitor
patients treated with a high dose of GS-0976 had a reduction in liver
fat, compared with 15% with placebo. GS-0976 patients also had
larger reduction in TIMP-1, but there was no difference with placebo
in liver stiffness, serum ALT, or PIII-NP.
NGM
FGF19 analog
NGM Biopharmaceuticals announced that in an 82-patient, 12Biopharmaceuticals
week, phase II trial, patients treated with NGM282 had a 10%-12%
reduction in liver fat compared with placebo. 34% of patients reached
normal levels of liver fat content.

Source. Information adapted from the Prescribe Right Pharmaceutical Pipeline Tracker database.9
Note. NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis; CCR2 = C-C chemokine receptor type 2; CCR5 = C-C chemokine
receptor type 5; PPAR = peroxisome proliferator-activated receptor agonist; ASK1 = apoptosis signal-regulating kinase 1; MELD = model for end-stage
liver disease; Acetyl-CoA = acetyl coenzyme A; TIMP-1 = tissue inhibitor of metalloproteinase 1; ALT = alanine transaminase; PIII-NP = amino terminal
propeptide of type III procollagen; FGF19 = fibroblast growth factor 19.

Author's Note
Information is summarized from selected materials; additional information may be available from other sources. Due to the preapproval nature of
the information, non-peer-reviewed data may be utilized. The information provided is meant to provide a way to assess the development status
of a new drug and should not be used in making patient care decisions.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1.

Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin
North Am. 2016;45(4):639-652.
Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third
National Health and Nutrition Examination Survey, 19881994. Am J Epidemiol. 2013;178(1):38-45.
Younossi ZM, Otgonsuren M, Henry L, et al. Association of
nonalcoholic fatty liver disease (NAFLD) with hepatocellular

carcinoma (HCC) in the United States from 2004 to 2009.
Hepatol. 2015;62:1723-1730.
Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba
R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of
paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):
643-654.
Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD):
a systematic review and meta-analysis of randomised trials.
Diabetologia. 2012;55:885-904.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis
and management of nonalcoholic fatty liver disease: practice
guidance from the American Association for the Study of
Liver Diseases. Hepatology. 2018;67(1):328-357. doi:10.1002/
hep.29367.
Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile
acid conjugate aramchol reduces liver fat content in patients
with nonalcoholic fatty liver disease. Clin Gastroenterol
Hepatol. 2014;12(12):2085-2091.
Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor
selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018;67(2):549-559.
Prescribe Right Pharmaceutical Pipeline Tracker. 2018. http://
www.prescriberight.com/pharmaceutical-pipeline-tracker.
html. Accessed February 1, 2018.

http://www.prescriberight.com/pharmaceutical-pipeline-tracker.html http://www.prescriberight.com/pharmaceutical-pipeline-tracker.html http://www.prescriberight.com/pharmaceutical-pipeline-tracker.html

Table of Contents for the Digital Edition of Hospital Pharmacy - June 2018